Modality
Radioligand
MOA
IL-13i
Target
WRN
Pathway
Notch
DLBCL
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
Apr 2021
→ Aug 2028
Phase 2Current
NCT04205115
1,461 pts·DLBCL
2021-04→2028-08·Not yet recruiting
1,461 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-022.3y awayPh3 Readout· DLBCL
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2/3
Not yet…
Catalysts
Ph3 Readout
2028-08-02 · 2.3y away
DLBCL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04205115 | Phase 2/3 | DLBCL | Not yet recr... | 1461 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN |